An Open Label Clinical Study To Evaluate Tanruprubart (Also Commonly Known As ANX005) In Participants With Guillain-Barré Syndrome (FORWARD Study)
Jacksonville, FL; Rochester, MN
The goal of this open label study is to measure pharmacokinetics, pharmacodynamics, early efficacy, and safety of tanruprubart in adult and pediatric participants, in the United States, Canada, and Europe.